Randomized Trial of Lactin-V to Prevent Recurrence of Bacterial Vaginosis

RCT (n=228) found use of Lactobacillus crispatus CTV-05 (Lactin-V) after vaginal metronidazole resulted in lower incidence of recurrence of bacterial vaginosis than placebo at 12 weeks [recurred in 46 (30%) vs. 34 (45%), respectively;risk ratio 0.66; 95% CI, 0.44 to 0.87; p=0.01]


New England Journal of Medicine